Homepage-10

Engineering Future Medicines

GENY commercialises highly potent antibodies for infectious diseases and cancer. Using a unique technological platform, we take blood from convalescent patients to identify the natural, fully human antibodies that resolved their infection.

About Us

GENY Biologics was formed in 2020 to license and commercialise superior antibody technologies derived from state-of-the-art technological platforms, through an exclusive technology licence with National University of Singapore.

Based in co11ab, Singapore’s first incubator located in the heart of Novena health hub, GENY is strategically positioned to tap into a wealth of expertise from clinicians, scientists and Singapore’s top innovation experts.

What We Do

Using multiple antibody discovery platforms, together with a full suite of protein engineering, we transition technologies from the research lab, through small scale testing and prototype development, taking them all the way to market.

Delivering new solutions, improving
outcomes for patients

Investors

GENY Biologics has an exciting portfolio of unique and highly effective monoclonal antibodies for the diagnosis and treatment of infectious deseases and cancer. 

Our current focus is on developing an accurate, sensitive point-of-care test for early stage serotype-specific diagnosis of dengue virus infection-a game changer for rapid diagnosis in rural areas. GENY is offering an attractive co-investment opportunity creating extra value for new investors. 

Latest News

A fast, sensitive laboratory test for detecting neutralising antibodies to SARS-CoV-2 viral variants in serum or plasma.

GENY’s ImTracker SARS-C0V-2 viral variant neutralization test is a serological enzyme-linked immunosorbent assay (ELISA) that identifies neutralizing antibodies that are able to block infection by the latest viral variants that cause Covid. The ImTracker test has been granted the European Conformity CE Mark, and is available as an In Vitro Diagnostic (IVD) or for research use (RUO).

RBD viral variant proteins are available individually, including several Omicron sub-variants XBB and XBB.1.5.  We also provide a custom service for research use. See Order Products section, or contact us for custom service.

GENY Biologics dengue treatment featured on Channel News Asia

Kill the dengue virus in 6 hours instead of 2 weeks? Associate Professor Paul MacAry and his team from the Immunology Translational Research Programme at the National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine) isolated a human antibody after screening “literally hundreds of millions” of antibodies derived from individuals who had recovered from dengue serotype 1. See the video of the interview with him.